查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1840827

按药物类型、剂型、製造阶段、分子类型、製造技术、最终用户和治疗领域分類的製药製造市场 - 全球预测 2025-2032

Pharmaceutical Manufacturing Market by Drug Type, Dosage Form, Manufacturing Stage, Molecule Type, Manufacturing Technology, End-User, Therapeutic Area - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，製药製造市场规模将成长至 13,353.4 亿美元，复合年增长率为 8.95%。

主要市场统计数据
基准年2024年 6724.4亿美元
预计2025年 7316.3亿美元
预测年份：2032年 13,353.40亿美元
复合年增长率（%） 8.95%

製药业正处于关键的十字路口，经营团队需要在业务永续营运与加速技术创新之间取得平衡。供应链中断、全球贸易政策变化以及日益复杂的监管，与生物加工、数位化和一次性技术的快速发展交织在一起，为整个製造业带来了风险和机会。高阶领导者必须在短期韧性措施与释放长期竞争优势的投资之间取得平衡，同时将竞争和病人安全置于每个决策的核心。

因此，策略规划需要多维度观点，将采购弹性、製造模组化和员工能力建构融为一体。这个观点强调需要灵活的製造平台，能够支援小分子和大分子模式、分散式或契约製造关係，以及在适当情况下混合批量和连续式生产。同时，监管机构、付款人和患者等相关人员的严格审查也要求建立透明的品质系统和强大的资料管理。

本摘要概述了影响製造选择的最重要变化，检验了关税对采购和契约製造的影响，并提供了可行的细分和区域见解，指南资源分配和伙伴关係策略。

变革性转变透过数位化、永续性要求、劳动力变革和供应链重建重新定义製药製造业

技术成熟度与不断变化的监管预期相结合，正在改变药品的开发、生产和交付方式。数位化，包括先进的过程分析、即时监控和预测性维护，正在从先导计画转向生产关键系统。同时，永续性的要求和减少环境足迹的动力正在改变设备设计和耗材选择，鼓励采用资源高效的一次性系统和环保公用设施。

融合流程工程、资料科学和监管专业知识的混合技能组合正变得至关重要。随着某些技术领域人才短缺的出现，企业越来越依赖伙伴关係和专业承包机构来填补能力缺口。供应链重组也是一个关键主题，企业正在多元化其供应商基础，将战略部件回流到国内，并采用多源采购策略，以减少地缘政治和物流中断带来的风险。总而言之，这些转变需要一个能够协调资本配置、技术蓝图和人才发展的综合管治模式，以获得竞争优势。

分析2025年美国关税对药品製造成本、筹资策略、契约製造和全球采购模式的累积影响

2025年美国关税和贸易政策调整为全球医药生产网络带来了新的限制和决策点。采购团队正在重新评估供应商合约和总到岸成本，并再次强调供应商多元化、关键投入的近岸外包以及稳定供应的长期框架协议。在此背景下，製造商正在重新评估其原料药和特殊原料的筹资策略，优先考虑供应的连续性和资格确认速度，而不仅仅是最低单价。

随着客户在本地化产能与维持灵活的外部生产线之间权衡利弊，受託製造製造商的需求模式正在改变。为此，许多公司正在加快谈判，以建立产能保障，并为其他CMO提供快速资格确认途径。此外，采购管治也变得更加动态，使用基于情境的风险评估来优先考虑能够提供技术支援、冗余和地理分布的供应商。

最终，关税带来的压力促使人们重新关注供应链视觉性、协作供应商关係以及更复杂的采购分析。这些功能支援快速调整生产流程的优先级，并使领导团队能够做出在成本、速度和合规应对力取得平衡的防御性决策。

整合药物类型、剂型、製造阶段、分子类型、技术、最终用户和治疗领域的关键细分洞察，以支持策略性产品决策

细分提供了一个框架，用于解释价值、风险和机会在製药生产全过程中的交汇点。按药物类型考虑，生物相似药、原厂药和学名药之间的差异会影响对生技药品生产设施的投资优先级、所需监管文件的深度以及支持治疗差异化的製造复杂程度。基于剂型的决策必须反映每种剂型独特的营运要求：液体剂型，包括乳剂、溶液和混悬液的生产；预填充式注射器剂型，包括输液和注射剂型，并额外考虑预充式註射器和管瓶；以及固态剂型，具有支持胶囊、粉剂和片剂生产的不同生产线和设施。此外，製造阶段（例如原料药製造、製剂製造以及包装和贴标）之间的差异决定了品管资源和製程验证工作的重点。

分子类型也会影响策略。大分子药物需要专门的生物製程设备和低温运输能力，而小分子药物通常受益于成熟的化学合成平台和不同的监管测试途径。批量、连续或一次性技术的选择会影响灵活性、转换时间表和污染控制策略。最后，最终用户的考虑因素——包括生物技术公司、合约研究组织、政府和公共卫生机构、製药公司以及研究和学术机构——以及心血管、循环系统、胃肠病学、免疫学、传染病、神经病学、感染疾病学、罕见疾病和呼吸系统等治疗领域——决定了需求概况和所需的製造吞吐量。解读这种多层次的细分有助于制定有针对性的资本规划和产品策略调整。

主要区域亮点集中在美洲、欧洲、中东和非洲以及亚太地区的供应链弹性、监管趋同、投资动态和创新热点

区域动态显着影响製造策略、投资地点和监管互动。美洲地区在产能扩张和伙伴关係采取了务实的做法，该地区继续优先发展扩充性的无菌和生技药品生产能力，同时充分利用支持国内生产的当地监管要求和奖励。欧洲、中东和非洲的监管和商业惯例各不相同，需要製定细緻入微的策略。儘管某些地区的监管协调与其他地区的产能限制和独特的市场进入路径并存，但企业可能会采用模组化、出口导向的营运模式。亚太地区是临床供应和大批量生产的焦点，多个市场迅速采用连续使用和一次性使用技术，并拥有良好的製造生态系统和熟练的人才库。

在这些地区，跨国製造商越来越多地寻求混合布局，将区域卓越中心与分散式生产节点结合，以优化前置作业时间并降低地缘政治风险。投资决策反映了当地的奖励、人才供应以及与关键市场和合作伙伴的接近性。因此，区域策略如今强调监管协调、跨辖区的严格品质监督以及灵活的营运模式，这些模式可以根据市场需求的变化进行扩展和调整。

主要企业对製药业策略定位、技术采用、合作模式、产能投资和竞争差异化的见解

主要企业正透过技术投资、策略伙伴关係和有针对性的产能扩张等多种方式脱颖而出。一些製造商优先考虑数位转型，以实现端到端的可视性和预测性品质体系，而另一些製造商则将资金集中于生技药品套件和一次性平台，以抓住复杂模式的成长机会。伙伴关係模式也日趋多样化，技术许可、合约设施共同投资以及与研究机构的扩大合作已成为加速产能推出和获取专业技术的标准机制，而无需承担全部内部开发成本。

竞争动态也反映了垂直整合和外包的不同方法。拥有深厚内部能力的公司寻求自行管理关键流程，而那些优先考虑速度和灵活性的公司则利用与高品质製造外包的伙伴关係。在整个行业中，高度重视人才供应、卓越的监管和持续改进计划仍然是市场领导的标誌。那些优先考虑无菌製造、生技药品和快速响应能力等领域，并将营运投资与清晰的产品市场策略相结合的公司，最有能力将策略意图转化为可衡量的营运成果。

为产业领导者提供切实可行的建议，重点在于营运敏捷性、数位转型规划、劳动力策略、製造创新和弹性采购

产业领导者应采取一系列平衡的行动，在促进创新的同时增强韧性。首先，采用模组化和灵活的製造架构，实现产品类型的快速切换，并在适当情况下支援批量和连续加工。其次，透过实施先进的製程控制、即时放行测试能力和分析主导的维护计划，加速整个生产生命週期的数位化集成，以提高产量比率并缩短放行时间。第三，透过有针对性的招募、交叉训练和学术合作，培养一支融合程式工程、品质保证和数据分析的员工队伍。

此外，透过多源策略和与供应商的深入合作（包括技术支援和联合风险缓解计划）来优化采购。选择性地投资一次性技术和绿色公用事业，在不影响生产可靠性的情况下实现永续性目标。最后，优先考虑与集体管理组织 (CMO) 的合约灵活性，并制定快速资格认证途径，以确保在电价调整、监管变化和需求激增等情况下的连续性。综上所述，这些建议为寻求保护近期业务并为未来产品和市场扩张做好准备的高阶主管提供了切实可行的蓝图。

调查方法：一手资料和二手资料研究、专家访谈、资料三角检验、检验通讯协定以及研究设计中的限制细节

调查方法采用多层次方法，结合一手资料研究、二手资料整合和系统性资料检验，以确保获得可靠且可操作的洞察。一手资料包括与製造企业营运、品质、采购和策略部门的高层领导以及法规事务和製造技术专家进行结构化访谈。这些对话提供了关于营运限制、技术采用时间表和采购行为的真实观点。二手资料研究则利用专家同行评审文献、监管指南文件、技术白皮书和原始技术报告，以揭示观察到的趋势的背景和历史先例。

资料三角测量技术将定性输入与已记录的监管变化和已发布的技术标准进行交叉核对，以最大限度地减少偏差并检验新兴主题。检验方案包括与独立专家的最后覆核和迭代审查週期，以完善关于技术就绪度和供应链行为的假设。本调查方法承认产业分析的典型局限性，例如公司层级资讯揭露的差异以及贸易政策的动态性。然而，一手证据与严格检验的结合，为本摘要阐述的方向性和策略性建议增添了可信度。

结论整合了战略要务、风险管理重点、创新途径以及弹性和可扩展製药製造的前景

综合洞察表明，韧性製药製造业依赖一种整合的方法，该方法能够协调技术应用、供应链策略、监管参与和人才发展。优先考虑灵活製造平台、投资数位化品质生态系统并积极实现关键供应商多元化的组织，将能够更好地应对政策驱动的衝击和对复杂生技药品日益增长的需求。同样重要的是，需要建立一种能够快速重新分配资源、加快供应商资格确认并在多个司法管辖区保持合规性的管治模式。

展望未来，高阶主管必须在持续改善现有营运与规划投资下一代处理和分析技术之间取得平衡。这种双重关注使企业能够保持近期生产稳定，同时建立释放未来效率和治疗机会的能力。实际上，成功的实施取决于严谨的资本配置、清晰的技术蓝图，以及与能够提供专业能力、监管支援和技术诀窍的外部合作伙伴的持续合作。最终，韧性和适应性将决定哪些组织能够在日益复杂的全球环境中始终如一地提供高品质的产品。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 将具有即时品质监控功能的连续流反应器引入活性药物成分的合成
  • 推出先进的一次性生物反应器系统，实现灵活的细胞培养製造
  • 将人工智慧驱动的预测分析融入生物製药製造的製程优化中
  • 实施数位双胞胎技术，实现端到端透明度
  • 利用模组化设施设计和自动化扩大 mRNA 疫苗生产
  • 应用新型绿色溶剂技术增强药物化合物的永续萃取
  • 利用基于区块链的低温运输追踪解决方案增强供应链弹性

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第 8 章：按药品类型分類的製药製造市场

  • 生物相似药
  • 品牌药
  • 学名药

第九章 药品製造市场（以剂型）

  • 液体剂型
    • 乳剂
    • 解决方案
    • 暂停
  • 肠外剂型
    • 输液形式
    • 注射
      • 预填充式注射器
      • 管瓶
  • 固态剂型
    • 胶囊
    • 粉末
    • 药片

第 10 章：按製造阶段分類的製药製造市场

  • API製造
  • 製药製造业
  • 包装和标籤

第 11 章：按分子类型分類的製药製造市场

  • 聚合物药物
  • 小分子药物

第12章：製药製造市场製造技术

  • 大量生产
  • 常规製造
  • 免洗技术

第 13 章：药品製造市场（依最终用户划分）

  • 生技公司
  • 合约研究组织（CRO）
  • 政府/公共卫生机构
  • 製药公司
  • 研究和学术机构

第 14 章：按治疗领域分類的製药製造市场

  • 心血管系统
  • 内分泌学（例如糖尿病）
  • 胃肠病学
  • 免疫学
  • 感染疾病
  • 神经病学
  • 肿瘤学
  • 罕见疾病
  • 呼吸系统

第 15 章：按地区分類的製药製造市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第 16 章：按类别分類的製药製造市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 17 章：各国製药製造市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十八章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Pfizer Inc.
    • Roche Holding AG
    • Johnson & Johnson
    • Merck KGaA
    • Novartis AG
    • AbbVie Inc.
    • Sanofi SA
    • AstraZeneca plc
    • Eli Lilly and Company
    • ACG Pvt. Ltd.
    • Mankind Pharma Ltd.
Product Code: MRR-22146147675F

The Pharmaceutical Manufacturing Market is projected to grow by USD 1,335.34 billion at a CAGR of 8.95% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 672.44 billion
Estimated Year [2025] USD 731.63 billion
Forecast Year [2032] USD 1,335.34 billion
CAGR (%) 8.95%

The pharmaceutical manufacturing landscape is at a pivotal juncture as executives balance operational continuity with accelerated innovation imperatives. Supply chain disruptions, shifts in global trade policy, and mounting regulatory complexity have converged with rapid advances in bioprocessing, digitization, and single-use technologies to create both risk and opportunity across manufacturing footprints. Senior leaders must reconcile short-term resilience measures with investments that unlock long-term competitive advantage, while ensuring compliance and patient safety remain central to all decisions.

Consequently, strategic planning now requires a multi-dimensional perspective that integrates sourcing flexibility, manufacturing modularity, and workforce capability building. This perspective emphasizes the need for flexible production platforms that can support both small molecule and large molecule modalities, decentralized or contract manufacturing relationships, and a blend of batch and continuous processing where appropriate. In parallel, increasing stakeholder scrutiny-spanning regulators, payers, and patients-demands transparent quality systems and robust data stewardship.

In the sections that follow, the summary synthesizes the most consequential shifts shaping choices across manufacturing stages, examines tariff-driven implications for procurement and contract manufacturing, and presents actionable segmentation and regional insights to guide resource allocation and partnership strategies.

Transformative shifts redefining pharmaceutical manufacturing through digitalization, sustainability mandates, workforce evolution, and supply chain reconfiguration

Transformative forces are reshaping how pharmaceutical products are developed, manufactured, and delivered, driven by a combination of technological maturation and evolving regulatory expectations. Digitalization, including advanced process analytics, real-time monitoring, and predictive maintenance, is transitioning from pilot projects to production-critical systems; this transition enables quality by design approaches and reduces time-to-release through data-rich control strategies. At the same time, sustainability mandates and a push for reduced environmental footprint are changing facility design and consumable choices, encouraging adoption of resource-efficient single-use systems and greener utilities.

Workforce evolution also matters: hybrid skill sets that combine process engineering, data science, and regulatory know-how are now essential. As human capital becomes scarcer in specific technical domains, organizations increasingly rely on partnerships and specialized contract organizations to bridge capability gaps. Supply chain reconfiguration is another key theme, with firms diversifying supplier bases, reshoring strategic components, and adopting multi-sourcing strategies to lower exposure to geopolitical and logistical disruptions. Taken together, these shifts require integrated governance models that align capital allocation, technology roadmaps, and talent development in a coordinated manner to seize competitive advantage.

Analysis of cumulative impact of United States tariffs in 2025 on drug production costs, sourcing strategies, contract manufacturing, and global procurement models

The introduction of tariffs and trade policy adjustments by the United States in 2025 introduced new constraints and decision points across global pharmaceutical production networks. Procurement teams have moved to reassess supplier contracts and total landed cost considerations, placing renewed emphasis on supplier diversity, nearshoring of critical inputs, and long-term framework agreements to stabilize supply. In this context, manufacturers are recalibrating sourcing strategies for active pharmaceutical ingredients and specialized raw materials, with a stronger premium placed on supply continuity and qualification speed rather than lowest unit cost alone.

Contract manufacturing organizations have experienced shifts in demand patterns as clients evaluate the trade-offs between localizing capacity and preserving flexible external production lanes. In response, many organizations have accelerated negotiations to secure guaranteed capacity or to establish rapid qualification pathways for alternative CMOs. Additionally, procurement governance has become more dynamic, using scenario-based risk assessments to prioritize suppliers that provide technical support, redundancy, and geographic diversification.

Ultimately, tariff-induced pressures have prompted a renewed focus on supply chain visibility, collaborative supplier relationships, and more sophisticated procurement analytics. These capabilities support faster reprioritization of production flows and enable leadership teams to make defensible choices that balance cost, speed, and regulatory readiness.

Key segmentation insights integrating drug type, dosage forms, manufacturing stages, molecule types, technologies, end-users, and therapeutic areas to inform strategic product decisions

Segmentation provides a framework to interpret where value, risk, and opportunity intersect across the pharmaceutical manufacturing continuum. When examined by drug type, differences between biosimilars, branded drugs, and generic drugs influence prioritization of investment in biologics-capable facilities, the depth of regulatory dossiers required, and the degree of manufacturing complexity to support therapeutic differentiation. Based on dosage form, decision making must reflect the specific operational requirements of liquid dosage forms including emulsion, solution, and suspension processing; parenteral dosage forms which cover infusion forms and injectable forms with further considerations for prefilled syringe and vial production; and solid dosage forms where distinct lines and tooling support capsule, powder, and tablet manufacturing. Across manufacturing stage, distinctions between API manufacturing, formulation manufacturing, and packaging and labelling drive where quality control resources and process validation efforts concentrate, and each stage carries different capital intensity and scale considerations.

Molecule type also shapes strategy: large molecule drugs demand specialized bioprocessing suites and cold-chain readiness, while small molecule drugs generally benefit from established chemical synthesis platforms and different regulatory testing pathways. Manufacturing technology selection further differentiates operations; whether organizations opt for batch manufacturing, continuous manufacturing, or single-use technology affects flexibility, changeover timelines, and contamination control strategies. Finally, end-user considerations-spanning biotechnology companies, contract research organizations, government and public health bodies, pharmaceutical companies, and research organizations and academic institutes-along with therapeutic area focus across cardiovascular, endocrinology, gastroenterology, immunology, infectious diseases, neurology, oncology, rare diseases, and respiratory fields, determine demand profiles and required manufacturing throughput. Interpreting segmentation in this layered fashion enables targeted capital planning and product strategy alignment.

Key regional insights highlighting supply chain resilience, regulatory convergence, investment dynamics, and innovation hotspots across Americas, Europe, Middle East & Africa, Asia-Pacific

Regional dynamics materially influence manufacturing strategy, investment location, and regulatory interaction. In the Americas, pragmatic approaches to capacity expansion and partnerships are evident, and the region continues to prioritize scalable sterile and biologics manufacturing capabilities while navigating local regulatory expectations and incentives that support domestic production. Europe, Middle East & Africa presents a heterogeneous regulatory and commercial landscape that requires nuanced engagement strategies; progressive regulatory harmonization in some jurisdictions coexists with capacity constraints and distinct market access pathways in others, prompting firms to adopt modular and export-oriented operational models. Asia-Pacific remains a focal point for both clinical supply and mass production, with several markets demonstrating rapid adoption of continuous and single-use technologies alongside favorable manufacturing ecosystems and skilled talent pools.

Across these regions, multinational manufacturers increasingly pursue hybrid footprints that combine regional centers of excellence with distributed production nodes to optimize lead times and mitigate geopolitical risk. Investment decisions reflect local incentives, talent availability, and proximity to key markets and partners. Consequently, regional strategies now emphasize regulatory alignment, robust quality oversight across jurisdictions, and flexible operational models that can be scaled or repurposed as market requirements evolve.

Key companies insights examining strategic positioning, technology adoption, partnership models, capacity investments, and competitive differentiation in the pharmaceutical sector

Leading companies are differentiating through combinations of technological investment, strategic partnerships, and targeted capacity expansion. Some manufacturers are prioritizing digital transformation to enable end-to-end visibility and predictive quality systems, while others focus capital on biologics suites and single-use platforms to capture growth in complex modalities. Partnership models have diversified; technology licensing, co-investment in contract facilities, and expanded collaboration with research institutions have become standard mechanisms to accelerate time-to-capacity and to access specialized skills without incurring the full cost of internal development.

Competitive dynamics also reflect varied approaches to vertical integration and outsourcing. Firms with deep internal capabilities seek to preserve proprietary control over critical processes, while those emphasizing speed and flexibility leverage partnerships with high-quality contract manufacturing organizations. Across the sector, emphasis on talent retention, regulatory excellence, and continuous improvement programs remains a defining attribute of market leaders. Companies that align operational investments with a clear product and market strategy-prioritizing areas such as sterile manufacturing, biologics, or rapid-response capacity-have positioned themselves to convert strategic intent into measurable operational outcomes.

Actionable recommendations for industry leaders focused on operational agility, digital transformation plans, talent strategies, manufacturing innovation, and resilient procurement

Industry leaders should pursue a balanced set of actions that strengthen resilience while enabling innovation. First, adopt modular and flexible manufacturing architectures that allow rapid changeover between product types and support both batch and continuous processing when appropriate; this reduces downtime and supports demand variability. Second, accelerate digital integration across the production lifecycle by implementing advanced process control, real-time release testing capabilities, and analytics-driven maintenance programs to improve yield and shorten release timelines. Third, cultivate workforce capabilities that blend process engineering, quality assurance, and data analytics through targeted hiring, cross-training, and partnerships with academic institutions.

Moreover, optimize procurement through multi-sourcing strategies and deeper supplier collaboration that includes technical support and joint risk mitigation planning. Invest selectively in single-use technologies and green utilities to meet sustainability goals without compromising production reliability. Finally, prioritize contractual flexibility with CMOs and develop rapid qualification pathways to ensure continuity in scenarios of tariff shifts, regulatory changes, or demand spikes. Taken together, these recommendations create a pragmatic roadmap for executives seeking to protect short-term operations while positioning the organization for future product and market expansion.

Research methodology detailing primary and secondary approaches, expert interviews, data triangulation techniques, validation protocols, and limitations of the study design

The research methodology employed a layered approach combining primary interviews, secondary source synthesis, and systematic data validation to ensure robust and actionable insights. Primary inputs included structured interviews with senior operations, quality, procurement, and strategy leaders across manufacturing organizations, as well as subject matter experts in regulatory affairs and manufacturing technology. These conversations provided ground-truth perspectives on operational constraints, technology adoption timelines, and procurement behavior. Secondary research drew on peer-reviewed literature, regulatory guidance documents, technical white papers, and proprietary technical reports to establish context and historical precedent for observed trends.

Data triangulation techniques matched qualitative inputs against documented regulatory changes and published technical standards to minimize bias and validate emergent themes. Validation protocols included cross-checks with independent experts and iterative review cycles to refine assumptions about technology readiness and supply chain behavior. The methodology acknowledges limitations typical of industry analysis, including variability in firm-level disclosure and the dynamic nature of trade policy. However, the combined use of primary evidence and rigorous validation strengthens confidence in the directional implications and strategic recommendations articulated in this summary.

Conclusion synthesizing strategic imperatives, risk management priorities, innovation pathways, and the outlook for resilient and scalable pharmaceutical manufacturing

The synthesis of insights demonstrates that resilient pharmaceutical manufacturing will depend on an integrated approach that aligns technology adoption, supply chain strategy, regulatory engagement, and human capital development. Organizations that prioritize flexible manufacturing platforms, invest in digital quality ecosystems, and preemptively diversify critical suppliers will be better positioned to navigate both policy-induced shocks and accelerating demand for complex biologics. Equally important is the need for governance models that enable rapid reallocation of resources, expedite supplier qualification, and maintain regulatory compliance across multiple jurisdictions.

Looking ahead, executives must balance continuous improvement of current operations with deliberate investments in next-generation processing and analytics. This dual focus will enable firms to maintain short-term production stability while building capabilities that unlock future efficiencies and therapeutic opportunities. In practice, successful implementation will depend on disciplined capital allocation, clear technology roadmaps, and sustained engagement with external partners that can provide specialized capacity, regulatory support, and technical know-how. Ultimately, resilience and adaptability will distinguish organizations that can consistently deliver high-quality products in an increasingly complex global environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of continuous flow reactors with real-time quality monitoring in active pharmaceutical ingredient synthesis
  • 5.2. Deployment of advanced single-use bioreactor systems for flexible cell culture manufacturing
  • 5.3. Integration of AI-driven predictive analytics in process optimization for biologics production
  • 5.4. Implementation of digital twin technology for end-to-end pharmaceutical manufacturing transparency
  • 5.5. Scaling up mRNA vaccine production through modular facility design and automation
  • 5.6. Application of novel green solvent technologies to enhance sustainable drug compound extraction
  • 5.7. Enhancing supply chain resilience through blockchain-enabled cold chain tracking solutions

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Pharmaceutical Manufacturing Market, by Drug Type

  • 8.1. Biosimilars
  • 8.2. Branded Drugs
  • 8.3. Generic Drugs

9. Pharmaceutical Manufacturing Market, by Dosage Form

  • 9.1. Liquid Dosage Forms
    • 9.1.1. Emulsion
    • 9.1.2. Solution
    • 9.1.3. Suspension
  • 9.2. Parenteral Dosage Forms
    • 9.2.1. Infusion Forms
    • 9.2.2. Injectable Forms
      • 9.2.2.1. Prefilled Syringe
      • 9.2.2.2. Vial
  • 9.3. Solid Dosage Forms
    • 9.3.1. Capsule
    • 9.3.2. Powder
    • 9.3.3. Tablet

10. Pharmaceutical Manufacturing Market, by Manufacturing Stage

  • 10.1. API Manufacturing
  • 10.2. Formulation Manufacturing
  • 10.3. Packaging And Labelling

11. Pharmaceutical Manufacturing Market, by Molecule Type

  • 11.1. Large Molecule Drugs
  • 11.2. Small Molecule Drugs

12. Pharmaceutical Manufacturing Market, by Manufacturing Technology

  • 12.1. Batch Manufacturing
  • 12.2. Continuous Manufacturing
  • 12.3. Single-Use Technology

13. Pharmaceutical Manufacturing Market, by End-User

  • 13.1. Biotechnology Companies
  • 13.2. Contract Research Organizations (CROs)
  • 13.3. Government/Public Health Bodies
  • 13.4. Pharmaceutical Companies
  • 13.5. Research Organizations & Academic Institutes

14. Pharmaceutical Manufacturing Market, by Therapeutic Area

  • 14.1. Cardiovascular
  • 14.2. Endocrinology (e.g., Diabetes)
  • 14.3. Gastroenterology
  • 14.4. Immunology
  • 14.5. Infectious Diseases
  • 14.6. Neurology
  • 14.7. Oncology
  • 14.8. Rare Diseases
  • 14.9. Respiratory

15. Pharmaceutical Manufacturing Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Pharmaceutical Manufacturing Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Pharmaceutical Manufacturing Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2024
  • 18.2. FPNV Positioning Matrix, 2024
  • 18.3. Competitive Analysis
    • 18.3.1. Pfizer Inc.
    • 18.3.2. Roche Holding AG
    • 18.3.3. Johnson & Johnson
    • 18.3.4. Merck KGaA
    • 18.3.5. Novartis AG
    • 18.3.6. AbbVie Inc.
    • 18.3.7. Sanofi S.A.
    • 18.3.8. AstraZeneca plc
    • 18.3.9. Eli Lilly and Company
    • 18.3.10. ACG Pvt. Ltd.
    • 18.3.11. Mankind Pharma Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. NORTH AMERICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. LATIN AMERICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. EUROPE PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. MIDDLE EAST PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. AFRICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASEAN PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GCC PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. EUROPEAN UNION PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRICS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. G7 PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. NATO PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. PHARMACEUTICAL MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 34. PHARMACEUTICAL MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PHARMACEUTICAL MANUFACTURING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY BIOSIMILARS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY BIOSIMILARS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY BIOSIMILARS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY BIOSIMILARS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY BIOSIMILARS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY BIOSIMILARS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY BRANDED DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY BRANDED DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY BRANDED DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY BRANDED DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY BRANDED DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY BRANDED DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY GENERIC DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY GENERIC DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY GENERIC DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY GENERIC DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY GENERIC DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY GENERIC DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY EMULSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY EMULSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY EMULSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY EMULSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY EMULSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY EMULSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLUTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLUTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLUTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLUTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLUTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SUSPENSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SUSPENSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SUSPENSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INFUSION FORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INFUSION FORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INFUSION FORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INFUSION FORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INFUSION FORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INFUSION FORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INJECTABLE FORMS, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INJECTABLE FORMS, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INJECTABLE FORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INJECTABLE FORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INJECTABLE FORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INJECTABLE FORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INJECTABLE FORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INJECTABLE FORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PREFILLED SYRINGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PREFILLED SYRINGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PREFILLED SYRINGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PREFILLED SYRINGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY VIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY VIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY VIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY VIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY VIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY VIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY CAPSULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY CAPSULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY CAPSULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY POWDER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY POWDER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY POWDER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY POWDER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY POWDER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY POWDER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY API MANUFACTURING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY API MANUFACTURING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY API MANUFACTURING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY API MANUFACTURING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY API MANUFACTURING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY API MANUFACTURING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION MANUFACTURING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION MANUFACTURING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION MANUFACTURING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION MANUFACTURING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION MANUFACTURING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY FORMULATION MANUFACTURING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PACKAGING AND LABELLING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PACKAGING AND LABELLING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PACKAGING AND LABELLING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PACKAGING AND LABELLING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PACKAGING AND LABELLING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PACKAGING AND LABELLING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LARGE MOLECULE DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LARGE MOLECULE DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LARGE MOLECULE DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LARGE MOLECULE DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LARGE MOLECULE DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LARGE MOLECULE DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SMALL MOLECULE DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SMALL MOLECULE DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SMALL MOLECULE DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SMALL MOLECULE DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SMALL MOLECULE DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SMALL MOLECULE DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY BATCH MANUFACTURING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY BATCH MANUFACTURING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY BATCH MANUFACTURING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY BATCH MANUFACTURING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY BATCH MANUFACTURING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY BATCH MANUFACTURING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY CONTINUOUS MANUFACTURING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY CONTINUOUS MANUFACTURING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY CONTINUOUS MANUFACTURING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY CONTINUOUS MANUFACTURING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY CONTINUOUS MANUFACTURING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY CONTINUOUS MANUFACTURING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SINGLE-USE TECHNOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SINGLE-USE TECHNOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SINGLE-USE TECHNOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SINGLE-USE TECHNOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SINGLE-USE TECHNOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SINGLE-USE TECHNOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY GOVERNMENT/PUBLIC HEALTH BODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY GOVERNMENT/PUBLIC HEALTH BODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY GOVERNMENT/PUBLIC HEALTH BODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY GOVERNMENT/PUBLIC HEALTH BODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY GOVERNMENT/PUBLIC HEALTH BODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY GOVERNMENT/PUBLIC HEALTH BODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY RESEARCH ORGANIZATIONS & ACADEMIC INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY RESEARCH ORGANIZATIONS & ACADEMIC INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY RESEARCH ORGANIZATIONS & ACADEMIC INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY RESEARCH ORGANIZATIONS & ACADEMIC INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY RESEARCH ORGANIZATIONS & ACADEMIC INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY RESEARCH ORGANIZATIONS & ACADEMIC INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ENDOCRINOLOGY (E.G., DIABETES), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ENDOCRINOLOGY (E.G., DIABETES), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ENDOCRINOLOGY (E.G., DIABETES), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ENDOCRINOLOGY (E.G., DIABETES), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ENDOCRINOLOGY (E.G., DIABETES), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ENDOCRINOLOGY (E.G., DIABETES), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY GASTROENTEROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY GASTROENTEROLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY GASTROENTEROLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY GASTROENTEROLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY GASTROENTEROLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY GASTROENTEROLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY IMMUNOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY IMMUNOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY IMMUNOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY IMMUNOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY NEUROLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY RARE DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY RARE DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY RESPIRATORY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY RESPIRATORY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY RESPIRATORY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY RESPIRATORY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY RESPIRATORY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INJECTABLE FORMS, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY INJECTABLE FORMS, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY SOLID DOSAGE FORMS, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING STAGE, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY MANUFACTURING TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. NORTH AMERICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. NORTH AMERICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA PHARMACEUTICAL MANUFACTURING MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2024 (USD MILLION)
  • TABLE 288. NORTH AMERICA PHARMACEUTICAL MANUFACTURING MARKET SIZE,